We are live on ! Find out more
CA

CHI Advisors Portfolio holdings

AUM $252M
1-Year Est. Return 56.99%
This Fund
S&P 500
This Quarter Est. Return
-1.53%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$281M
AUM Growth
+$24.9M
Cap. Flow
+$51.4M
Cap. Flow %
18.29%
Top 10 Hldgs %
95.45%
Holding
23
New
4
Increased
8
Reduced
7
Closed
1

Top Buys

Rank Stock Value
1
INZY
Inozyme Pharma
INZY
+$25.1M
2
FRLN
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
+$22.1M
3
AMWL icon
American Well
AMWL
+$6.55M
4
PLRX icon
Pliant Therapeutics
PLRX
+$1.16M
5
CRVS icon
Corvus Pharmaceuticals
CRVS
+$875K

Top Sells

Rank Stock Value
1
AKUS
Akouos Inc
AKUS
+$2.86M
2
LVGO
Livongo Health, Inc. Common Stock
LVGO
+$1.38M
3
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$691K
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$456K
5
KZR
Kezar Life Sciences
KZR
+$451K

Sector Composition

Rank Sector Weight
1 Healthcare 99.81%
2 Communication Services 0.18%
3 Miscellaneous 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RPTX
1
DELISTED
Repare Therapeutics
RPTX
$77.9M 27.7%
2,530,494
+27,086
+1% +$717K
PLRX icon
2
Pliant Therapeutics
PLRX
$71.2M
$53.3M 18.95%
2,352,291
+46,297
+2% +$1.16M
INZY
3
DELISTED
Inozyme Pharma
INZY
$26.5M 9.44%
+1,009,117
New +$25.1M
LRMR icon
4
Larimar Therapeutics
LRMR
$421M
$23M 8.18%
1,515,148
– –
KROS icon
5
Keros Therapeutics
KROS
$223M
$22M 7.81%
569,458
-10,286
-2% -$408K
FRLN
6
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$20.7M 7.35%
+88,291
New +$22.1M
AKUS
7
DELISTED
Akouos Inc
AKUS
$19.4M 6.89%
846,397
-128,588
-13% -$2.86M
ORTX
8
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$12M 4.29%
293,119
– –
AMWL icon
9
American Well
AMWL
$200M
$7.36M 2.62%
+12,418
New +$6.55M
DTIL icon
10
Precision BioSciences
DTIL
$232M
$6.25M 2.22%
33,828
+1,827
+6% +$363K
OVID icon
11
Ovid Therapeutics
OVID
$572M
$3.55M 1.26%
618,092
+73,811
+14% +$494K
CRVS icon
12
Corvus Pharmaceuticals
CRVS
$1.24B
$2.34M 0.83%
583,232
+219,100
+60% +$875K
KZR
13
DELISTED
Kezar Life Sciences
KZR
$1.19M 0.42%
24,664
-9,433
-28% -$451K
GTHX
14
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$970K 0.35%
84,000
+40,000
+91% +$660K
MYOK
15
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$954K 0.34%
7,000
-6,500
-48% -$691K
GBT
16
DELISTED
Global Blood Therapeutics, Inc.
GBT
$882K 0.31%
16,000
+3,000
+23% +$191K
ADVM
17
DELISTED
Adverum Biotechnologies
ADVM
$721K 0.26%
7,000
+2,000
+40% +$300K
RARE icon
18
Ultragenyx Pharmaceutical
RARE
$2.59B
$616K 0.22%
7,500
-5,500
-42% -$456K
BPMC
19
DELISTED
Blueprint Medicines
BPMC
$603K 0.21%
6,500
-5,500
-46% -$424K
LVGO
20
DELISTED
Livongo Health, Inc. Common Stock
LVGO
$510K 0.18%
3,640
-11,360
-76% -$1.38M
BLUE
21
DELISTED
bluebird bio
BLUE
$432K 0.15%
618
– –
GBT
22
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$26K 0.01%
+10,000
New +$636K
COGT icon
23
Cogent Biosciences
COGT
$6.44B
– –
-235,201
Closed -$433K

Similar funds

SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
T
TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return
W
WealthOne Albany, New York $248M AUM 17.79% 1-Year Est. Return
RBGI
Ribbit Bullfrog GP II Palo Alto, California $258M AUM 33.43% 1-Year Est. Return
TOGEPT
Trustees of General Electric Pension Trust Norwalk, Connecticut $245M AUM 128.88% 1-Year Est. Return
IAM
Innovis Asset Management Chicago, Illinois $260M AUM 28.13% 1-Year Est. Return
RCGI
Ribbit Capital GP II Palo Alto, California $260M AUM 2.87% 1-Year Est. Return
AEPLI
AH Equity Partners LSV III Menlo Park, California $262M AUM 59.24% 1-Year Est. Return

CHI Advisors's Q3 2020 Portfolio in Review

As of Q3 2020, CHI Advisors held 23 positions worth $281M, up 9.7% from $256M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

CHI Advisors deployed $51.4M of net new capital in Q3 2020, opening 4 new positions and adding to 8 existing holdings. Its largest new stake was Inozyme Pharma: 1,009,117 shares worth $26.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Communication Services and Miscellaneous.

On the sell side, the largest reduction was Akouos Inc, an estimated $2.86M trimmed.

  • CHI Advisors's largest Q3 2020 buy was Inozyme Pharma: 1,009,117 shares worth $26.5M.
  • CHI Advisors added most to Pliant Therapeutics in Q3 2020, an estimated $1.16M increase.
  • CHI Advisors's biggest Q3 2020 reduction was Akouos Inc, cutting an estimated $2.86M.
  • CHI Advisors fully exited Cogent Biosciences in Q3 2020, selling an estimated $433K.
  • CHI Advisors's ten largest holdings make up 95% of its $281M portfolio in Q3 2020.
  • CHI Advisors opened 4 new positions and closed 1 in Q3 2020.
  • CHI Advisors's portfolio value rose 9.7% quarter-over-quarter to $281M.

Based on CHI Advisors's 13F filing for Q3 2020, filed 12 Nov 2020.